CoChat
Sign Up
Cited by 590Immunotherapy and Immune ResponsesImmune cells in cancerT-cell and B-cell Immunology

The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.

Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor

Menetrier-Caux, C., Montmain, G., Dieu, M.C., Bain, C., Favrot, M.C., Caux, C., Blay, J.Y.·1998·Blood
DOI 10.1182/blood.v92.12.4778
Open this paper in CoChat — free account

Abstract

The escape of malignant cells from the immune response against the tumor may result from a defective differentiation or function of professional antigen-presenting cells (APC), ie, dendritic cells (DC). To test this hypothesis, the effect of human renal cell carcinoma cell lines (RCC) on the development of DC from CD34(+) progenitors was investigated in vitro. RCC cell lines were found to release soluble factors that inhibit the differentiation of CD34(+) cells into DC and trigger their commitment towards monocytic cells (CD14(+)CD64(+)CD1a-CD86(-)CD80(-)HLA-D Rlow) with a potent phagocytic capacity but lacking APC function. RCC CM were found to act on the two distinct subpopulations emerging in the culture at day 6 ([CD14(+)CD1a-] and [CD14(-)CD1a+]) by inhibiting the differentiation into DC of [CD14(+)CD1a-] precursors and blocking the acquisition of APC function of the [CD14(-)CD1a+] derived DC. Interleukin-6 (IL-6) and macrophage colony-stimulating factor (M-CSF) were found to be responsible for this phenomenon: antibodies against IL-6 and M-CSF abrogated the inhibitory effects of RCC CM; and recombinant IL-6 and/or M-CSF inhibited the differentiation of DC similarly to RCC CM. The inhibition of DC differentiation by RCC CM was preceeded by an induction of M-CSF receptor (M-CSFR; CD115) and a loss of granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR; CD116) expression at the surface of CD34(+) cells, two phenomenon reversed by anti-IL-6/IL-6R and anti-M-C…

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.v92.12.4778

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Négrier, 1996, The FNCLCC CRECY trial: Interleukin 2 (IL2) + interferon (IFN)-α is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC)., Proc Am Soc Clin Oncol, 15, 248

Cited by

Sorted by citations

Items 401–500 of 590

Related

See all

Metadata

Authors
Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y.
Affiliations
  • From Unité Cytokine et Cancer, Unité INSERM 453, Centre Léon Bérard, Lyon, France; and Schering Plough, Dardilly, France.
  • Inserm (FR)
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
1998-12-15
Volume
92
Issue
12
Pages
4778-4791
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood.v92.12.4778
OpenAlex
W193748226
Cited by
590
References
48
Citations by year
2026: 3 · 2025: 4 · 2024: 10 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 9 · 2016: 25 · 2015: 26 · 2014: 19 · 2013: 30 · 2012: 25
FWCI
6.33
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
dendritic cell differentiation, CD34+ progenitors, renal cell carcinoma, tumor immune evasion, interleukin-6, macrophage colony-stimulating factor, M-CSF receptor, GM-CSF receptor, antigen-presenting cells, monocyte differentiation, CD1a, CD14, soluble factors
MeSH terms
Antibodies, Carcinoma, Renal Cell, Cell Differentiation, Cell Division, Dendritic Cells, Dose-Response Relationship, Drug, Gene Expression Regulation, Humans, Lymphokines, Tumor Cells, Cultured, Interleukin-6, Immunophenotyping, Macrophage Colony-Stimulating Factor, Receptor, Macrophage Colony-Stimulating Factor, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor, Endothelial Growth Factors, Culture Media, Conditioned, Antigens, CD34, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Cell Size

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review